Physicians: Dermatologists, Urologists and other physician reporters
Case reporting is to be done through Web Plus. To set up a Web Plus user account or gain access to your facility’s account, please contact MCR. A Web Plus manual and instructions for use are found on the Web Plus page of this website under the “Reporting” header. More information and helpful screen shots can also be found in the Non-hospital Reporting Manual.
- Patient Information Sheet
- FAQs – Cancer Reporting for Dermatologists
- SEER Summary Staging – 2018: Summary staging is the most basic way of categorizing how far a cancer has spread from its point of origin. Summary staging has also been called General Staging, California Staging, and SEER Staging. The 2018 version of Summary Stage applies to every anatomic site, including the lymphomas and leukemias. Summary staging uses all information available in the medical record; in other words, it is a combination of the most precise clinical and pathological documentation of the extent of disease. This is the staging system required by the Center for Disease Control’s National Program of Cancer Registries (NPCR) as well as the North american association of Central Cancer Registries (NAACCR). Hospital registries approved by the Commission on Cancer use both the TNM Staging and the SEER Summary Staging. SEER Summary Staging (Melanomas)
- The cancer reporting form is available to facilities that report five (5) or fewer diagnosed or treated cancer cases per year
- Cancer Reporting Form Fillable (PDF) Instructions for Fillable Cancer Reporting Form (PDF)
Dermatologists
Reportable Cases:
Determination of whether or not a given primary neoplasm is reportable is made by reference to the histology and behavior codes of the International Classification of Diseases for Oncology, 3rd edition (ICD-O-3). The ICD-O-3 lists a preferred Histologic term along with synonyms, any of which applies. The following malignant and in situ neoplasms of the skin (C44) are reportable to MCR:
CODE | TERM |
---|---|
8247/3 | Merkel Cell Carcinoma |
8400/3 | Sweat Gland Adenocarcinoma |
8410/3 | Sebaceous Adenocarcinoma |
8720/2 | Melanoma In Situ |
8720/3 | Melanoma Malignant |
8721/3 | Melanoma Nodular |
8730/3 | Melanoma Amelanotic |
8742/2 | Lentigo Maligna |
8742/3 | Lentigo Maligna Melanoma |
8743/3 | Melanoma Superficial Spreading |
8772/3 | Melanoma Spindle Cell |
8800/3 | Sarcoma |
8810/3 | Fibrosarcoma |
8832/3 | Dermatofibrosarcoma |
8850/3 | Liposarcoma |
8890/3 | Leiomyosarcoma |
9140/3 | Kaposi Sarcoma |
9591/3 | Non-Hodgkin Lymphoma |
9650/3 | Hodgkin Lymphoma |
9680/3 | Diffuse Large B-Cell Lymphoma |
9700/3 | Mycosis Fungoides |
9709/3 | Cutaneous T-Cell Lymphoma |
Non-reportable Cases:
Basal cell and squamous cell carcinoma are not reported to MCR.